{
    "clinical_study": {
        "@rank": "41674", 
        "acronym": "ASSUAGE-MPI", 
        "arm_group": {
            "arm_group_label": "ASSUAGE Protocol", 
            "arm_group_type": "Experimental", 
            "description": "There is only one arm in this cross-over design trial. Patients who had a standard regadenoson stress test will be invited to enroll in the study. All enrolled subjects will undergo an investigational (ASSUAGE) regadenoson stress test. Imaging scans from the same patients (scan 1 and scan 2) will be compared."
        }, 
        "brief_summary": {
            "textblock": "The investigators developed a modified regadenoson nuclear stress test of the heart that\n      incorporates an aminophylline injection following regadenoson (The ASSUAGE protocol). The\n      modified (ASSUAGE) protocol has been associated with fewer side effects and was better\n      tolerated by patients.\n\n      This study will investigate whether the modified regadenoson stress protocol (ASSUAGE)\n      produces blood flow pattern to the heart similar to that of a standard regadenoson stress\n      protocol. In proven to be the case, the ASSUAGE protocol has the potential to be used on a\n      wide scale instead of the current standard protocol."
        }, 
        "brief_title": "The Impact of the Routine Aminophylline Administration Following Regadenoson Stress on SPECT Myocardial Perfusion", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Coronary Artery Disease", 
        "condition_browse": {
            "mesh_term": [
                "Coronary Artery Disease", 
                "Myocardial Ischemia", 
                "Coronary Disease"
            ]
        }, 
        "detailed_description": {
            "textblock": "Patients who had regadenoson stress nuclear stress test of the heart will be invited to\n      return to undergo a modified nuclear stress using the modified (ASSUAGE) protocol. Images\n      from the original scan will be compared to those from the second scan to determine whether\n      the blood flow pattern is similar between the two scans."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients who have had a qualifying regadenoson stress myocardial perfusion imaging\n             (regadenoson nuclear stress test).\n\n        Exclusion Criteria:\n\n          -  inability to provide an informed consent\n\n          -  known allergic reaction to aminophylline or regadenoson\n\n          -  systolic blood pressure < 90 mmHg\n\n          -  unstable abnormal heart rhythm\n\n          -  pulmonary edema\n\n          -  acute coronary symptoms, myocardial infarction within 48 hours\n\n          -  active dipyridamole, aminophylline or theophylline use\n\n          -  pregnancy\n\n          -  any contraindication to aminophylline according to the drug's package  insert:\n             uncontrolled seizure disorder, sepsis with multi-organ failure and liver impairment"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 26, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01655524", 
            "org_study_id": "ASSUAGE-MPI Trial"
        }, 
        "intervention": {
            "arm_group_label": "ASSUAGE Protocol", 
            "description": "75 mg of aminophylline injected intravenously 90 seconds following the radioisotope injection in the setting of regadenoson nuclear stress test of the heart.", 
            "intervention_name": "ASSUAGE Protocol", 
            "intervention_type": "Drug", 
            "other_name": "Aminophylline"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Aminophylline", 
                "Regadenoson"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Regadenoson", 
            "Aminophylline", 
            "ASSUAGE", 
            "Myocardial Perfusion Imaging (MPI)"
        ], 
        "lastchanged_date": "March 14, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Chicago", 
                    "country": "United States", 
                    "state": "Illinois", 
                    "zip": "60612"
                }, 
                "name": "Rush University Medical Center"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "The Impact of Routine Administration of Aminophylline Following Regadenoson According to the ASSUAGE Protocol on the Accuracy of Regadenoson Stress Myocardial Perfusion Imaging: A Single-Blinded Cross-Over Clinical Trial", 
        "other_outcome": {
            "description": "Agreement rate in the SDS burden category (normal/mild, moderate or severe)between scan 1 and scan 2 will be compared to the agreement rate between 2 sets of images from scan 1. The study is set out to demonstrate that these agreement rates are not significantly different.", 
            "measure": "Agreement rate in the size of blood flow abnormality category (none/small, moderate or large)", 
            "safety_issue": "No", 
            "time_frame": "within 4 weeks"
        }, 
        "overall_official": {
            "affiliation": "Rush University Medical Center", 
            "last_name": "Rami Doukky, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Suspended", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The SDS produced with standard protocol will be compared to SDS produced with the modified (ASSUAGE) protocol. The study is set out to demonstrate that there is no significant difference in SDS between the two protocols within the same patients.", 
            "measure": "Summed Difference Score (SDS); a measure of size and severity of  ischemia (heart muscle in jeopardy) detected with regadenoson nuclear stress of the heart (standard vs. ASSUAGE protocol).", 
            "safety_issue": "No", 
            "time_frame": "The second (investigational) stress will be performed within 4 weeks from the intial one."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01655524"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Agreement rate in the SDS burden category (normal/mild, moderate or severe)between scan 1 and scan 2 will be compared to the agreement rate between 2 sets of images from scan 1. The study is set out to demonstrate that these agreement rates are not significantly different.", 
            "measure": "Agreement rate in the SDS burden category (normal/mild, moderate or severe)", 
            "safety_issue": "No", 
            "time_frame": "within 4 weeks"
        }, 
        "source": "Rush University Medical Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Rush University Medical Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2012", 
        "study_design": "Endpoint Classification: Bio-equivalence Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic", 
        "study_type": "Interventional", 
        "verification_date": "July 2012", 
        "why_stopped": "Due to nationwide shortage of Aminophylline."
    }
}